Compare Gold Fields Limited (GFI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Novo Nordisk A/S — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 5.2× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Novo Nordisk A/S for 116 Days on average.
| GFI | NVO | |
|---|---|---|
Market Cap | $31.87B | $165.31B |
Volume | 4,169,651 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $63.98 |
52-Week Low | $31.25 | $35.29 |
Typical Hold Time | 49 Days | 116 Days |
Enterprise Value | $32.47B | $179.56B |
Dividend Yield | 6% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.82, up 5.05% today, amid mixed technical signals with a bearish overall trend. Fundamentally, the company shows strong profitability with 38.66% net margins and robust cash flow generation of $3.77B from operations in 2025. Recent news highlights the rejected $27B Northern Star takeover bid and strong operational performance from Salares Norte, driving investor attention to the company's capital allocation strategy.
The investment outlook balances strong fundamentals against acquisition risks and technical weakness. With 44% analyst buy ratings and a $52.75 price target suggesting 43% upside, GFI presents value opportunity, though recent earnings misses and bearish technicals warrant caution. Key risks include execution on growth projects and gold price volatility.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
